Nitric oxide synthase activity is increased in relation to the severity of liver dysfunction

1998 ◽  
Vol 95 (3) ◽  
pp. 355-359 ◽  
Author(s):  
Helen F. GALLEY ◽  
David COOMANSINGH ◽  
Nigel R. WEBSTER ◽  
Peter W. BRUNT

1.Nitric oxide is a potent vasodilator which plays a major role in the control of blood pressure. The hyperdynamic circulation of cirrhosis has been linked to nitric oxide. 2.We measured neutrophil nitric oxide synthase activity in relation to the level of hepatic dysfunction in patients with liver disease of varying aetiology and severity. 3.Neutrophils were isolated from 21 patients (7 Child-Pugh score A, 6 grade B and 8 grade C) aged 28–76 (median 49) years. Nitric oxide synthase activity was measured using the conversion of oxyhaemoglobin to methaemoglobin by nitric oxide and expressed in terms of cell protein. Blood pressure and biochemical indices were recorded. Data were assessed using Kruskal–Wallis one-way analysis of variance, Mann–Whitney U-test or Pearson correlation as appropriate. 4.Systolic, mean arterial and diastolic blood pressures decreased with increasing hepatic damage (P = 0.031, P = 0.01 and P = 0.038 respectively). Nitric oxide synthase activity increased with the degree of liver dysfunction (P = 0.033) and was highest in patients with Child-Pugh score C. Systolic blood pressure correlated with nitric oxide synthase activity in patients with Child-Pugh score C (P = 0.029). 5.Our results show that nitric oxide synthase activity increases with increasing Child-Pugh score and is associated with the development of systemic hypotension. These data may support the involvement of nitric oxide in the haemodynamic disturbances seen in liver disease.

1998 ◽  
Vol 95 (3) ◽  
pp. 355 ◽  
Author(s):  
Helen F. GALLEY ◽  
David COOMANSINGH ◽  
Nigel R. WEBSTER ◽  
Peter W. BRUNT

1995 ◽  
Vol 88 (2) ◽  
pp. 131-133 ◽  
Author(s):  
Helen F. Goode ◽  
Peter D. Howdle ◽  
Barry E. Walker ◽  
Nigel R. Webster

1. We measured nitric oxide synthase activity in peripheral blood polymorphonuclear leucocytes from 10 patients with sepsis syndrome and 10 healthy subjects. 2. Synthase activity was significantly higher in patients with sepsis than in control subjects (1202 ± 579 compared with 595 ± 544 pmol of nitric oxide min−1 mg−1 of cell protein, P < 0.05). 3. Activity was greatest in those patients with the larger number of organ failures, although this failed to reach significance (1489 ± 560 in patients with three or more organ failures and 843 ± 404 pmol of nitric oxide min−1 mg−1 of cell protein in those with less than three, P = 0.11). 4. This study provides evidence for the role of overproduction of the vasodilator nitric oxide in sepsis syndrome.


2002 ◽  
Vol 4 (1) ◽  
pp. 16-21 ◽  
Author(s):  
Brett M. Mitchell ◽  
R. Clinton Webb

Synthetic glucocorticoids are among the most widely prescribed medications by physicians. Although they have a vast array of beneficial effects such as immunosuppression and anti-inflammation, excess glucocorticoids can lead to iatrogenic Cushing’s syndrome, which includes hypertension and cardiovascular disease. The exact mechanism by which glucocorticoids elevate blood pressure is not completely understood, but it appears to be a complex pathology that involves increased responsiveness to vasoconstrictors and decreased vasodilator production. Nitric oxide is a vasodilator that plays a key role in blood pressure regulation, and previous studies have shown that a reduction in nitric oxide production or bioavailability contributes to hypertension. Tetrahydrobiopterin, a necessary cofactor for nitric oxide synthase activity, can affect nitric oxide production and bioavailability, with low levels causing decreased nitric oxide production. However, little is known about the interaction between glucocorticoids and tetrahydrobiopterin levels. In this review, the roles of nitric oxide and tetrahydrobiopterin in the pathogenesis of glucocorticoid hypertension will be discussed. Furthermore, the authors propose that glucocorticoids exert a genomic effect to decrease guanosine triphosphate cyclohydrolase I, the rate-limiting enzyme in the production of tetrahydrobiopterin. In the future, tetrahydrobiopterin supplementation in patients with iatrogenic Cushing’s syndrome may prove to be beneficial and decrease mortality attributed to cardiovascular disease.


2013 ◽  
Vol 40 (3) ◽  
pp. 197-204
Author(s):  
Megumi Tandai-Hiruma ◽  
Kazuo Kato ◽  
Takehito Kemuriyama ◽  
Hiroyuki Ohta ◽  
Akimasa Tashiro ◽  
...  

2005 ◽  
Vol 79 (12) ◽  
pp. 705-710 ◽  
Author(s):  
Yang Sun ◽  
Motoyuki Iemitsu ◽  
Nobutake Shimojo ◽  
Takashi Miyauchi ◽  
Masahiro Amamiya ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document